The quality of international normalised ratio control in southern Tasmania

Luke R E Bereznicki, Alexandra R Madden and Gregory M Peterson
Med J Aust 2013; 198 (6): . || doi: 10.5694/mja12.11370
Published online: 1 April 2013

To the Editor: The Australian Government’s recently completed Review of anticoagulation therapies in atrial fibrillation (AF) identified that the quality of international normalised ratio (INR) control was one of a number of factors creating uncertainty regarding the cost-effectiveness of novel anticoagulants in the Australian setting.1

  • Luke R E Bereznicki1
  • Alexandra R Madden2
  • Gregory M Peterson1

  • 1 School of Pharmacy, University of Tasmania, Hobart, TAS.
  • 2 Department of Pharmacy, Royal Hobart Hospital, Hobart, TAS.



We thank Peter Gee for analysing project data and Daniel Owens for facilitating access to pathology data and assisting with the project.

Competing interests:

Luke Bereznicki and Gregory Peterson have received consultancy fees from Aspen Pharmacare Australia and Boehringer Ingelheim. Luke Bereznicki has also received consultancy fees from Roche Diagnostics Australia and Sanofi Aventis, and speakers honoraria from Roche Diagnostics Australia and Boehringer Ingelheim.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.